CCR
Os receptores de quimiocinas C-C (CCRs) são um grupo de GPCRs que respondem às quimiocinas, moléculas de sinalização que orientam a migração de células imunológicas para locais de inflamação ou infecção. Os CCRs desempenham papéis cruciais nas respostas imunológicas, inflamação e no desenvolvimento de várias doenças, incluindo distúrbios autoimunes e câncer. A modulação da atividade dos CCRs está sendo explorada como uma estratégia terapêutica para condições como artrite reumatoide, esclerose múltipla e infecção pelo HIV. Na CymitQuimica, oferecemos uma gama de moduladores de CCR de alta qualidade para apoiar sua pesquisa em imunologia, inflamação e desenvolvimento terapêutico.
Foram encontrados 147 produtos para "CCR".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TBK1 degrader-4
TBK1degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. It effectively inhibits cyst growth, reduces inflammation, and lowers levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1degrader-4 shows potential for research in autosomal dominant polycystic kidney disease (ADPKD).Cor e Forma:Odour SolidPF-232798
CAS:PF-232798 is a second generation oral CCR5 antagonist with potent broad-spectrum anti-HIV-1 activity.Fórmula:C29H40FN5O2Cor e Forma:SolidPeso molecular:509.66CAP-100
CAP-100 is a monoclonal antibody targeting CCR7. It neutralizes the ligand binding site and signaling of CCR7. This compound effectively inhibits migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples induced by CCR7. CAP-100 can mediate potent tumor cell killing through host immune mechanisms and exhibits favorable toxicity profiles in related hematopoietic cell subsets. It is involved in research on antitumor activity and diseases like chronic lymphocytic leukemia (CLL).Cor e Forma:Odour LiquidMet-RANTES,human,acetate
Met-RANTES (human) acetate is the acetate salt form of Met-RANTES (human). It acts as an antagonist for CCR1 and CCR5 receptors. This compound inhibits the human chemokines MIP-1α and MIP-1β, with respective IC50 values of 5 and 2 nM. Additionally, Met-RANTES (human) acetate reduces bone destruction and alleviates adjuvant-induced arthritis (AIA) in rats.Cor e Forma:Odour SolidBMS-753426
CAS:BMS-753426 is a potent and orally bioavailable antagonist of CCR2 .Fórmula:C25H33F3N6O2Cor e Forma:SolidPeso molecular:506.574Plozalizumab
CAS:Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study ofPureza:96.4%Cor e Forma:Transparent LiquidPeso molecular:146.02 kDaCCR6 antagonist 1
CAS:CCR6 antagonist 1 blocks CCL20/CCR6, aiding autoimmune and IBD research.Fórmula:C17H12F3NO2Pureza:99.83%Cor e Forma:SolidPeso molecular:319.28Ref: TM-T60145
1mg34,00€2mg49,00€5mg74,00€1mL*10mM (DMSO)82,00€10mg105,00€25mg215,00€50mg313,00€100mg484,00€200mg683,00€CCR8 antagonist 1
CAS:CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.Fórmula:C26H29N3O5SPureza:99.51%Cor e Forma:SolidPeso molecular:495.59Bertilimumab
CAS:Bertilimumab (CAT 213; iCo-008), a human monoclonal antibody that targets eotaxin-1 (CCL11), shows promise in the research of allergic disorders [1].Cor e Forma:LiquidDenrakibart
Denrakibart is a humanized IgG2κ antibody targeting CCL17, with HumanIgG2kappa, Isotype Control serving as the corresponding isotype control.Cor e Forma:Odour LiquidZn-DPA-maytansinoid conjugate 1
Zn-DPA-maytansinoid 1 targets checkpoints, shrinks tumors, and heats TME.Fórmula:C115H145ClN18O31S2Zn2Cor e Forma:SolidPeso molecular:2505.83HGS004
HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. It exhibits potent antiviral activity against various CCR5-tropic HIV-1 strains, including those resistant to other treatments (such as Maraviroc-resistant strains). HGS004 is applicable for research in HIV-1 infection.Cor e Forma:Odour LiquidCCR4 antagonist 3 hydrochloride
CAS:Orally active CCR4 antagonist 3 hydrochloride with potent selectivity, IC50s: 22/50 nM; has antitumor properties.Fórmula:C24H27Cl2N7O·xHClCor e Forma:SolidCCR6 antagonist 2
CCR6 antagonist2 (Compound 20c) acts as a CCR6 antagonist with a Ki of 1.1 nM. It inhibits CCL20-induced calcium influx with an IC50 of 4.9 nM and suppresses the chemotactic migration of CCR6+ T cells with an IC50 of 190 nM.Fórmula:C19H24N4O4Cor e Forma:SolidPeso molecular:372.42INCB 3284 dimesylate
CAS:INCB 3284 dimesylate: oral CCR2 antagonist, blocks MCP-1/hCCR2 binding (IC50: 3.7 nM), potential in acute liver failure research.Fórmula:C28H39F3N4O10S2Pureza:98%Cor e Forma:SolidPeso molecular:712.76CCR4 antagonist 3
CAS:Orally active CCR4 antagonist with piperidinyl-azetidine; IC50: 22 nM (calcium flux), 50 nM (CTX); antitumor effects.Fórmula:C24H27Cl2N7OCor e Forma:SolidPeso molecular:500.43GSK163929
CAS:GSK163929 (compound 122) is an orally active CCR5 antagonist with anti-HIV properties and demonstrates low inhibitory potency against hEGR. Administered at a dosage of 2000 mg/kg/day (i.v., 7 d), it shows no adverse effects in rats, and at 250 mg/kg/day (i.v., 7 d), it is similarly non-toxic in dogs.Fórmula:C36H40ClF2N5O3SCor e Forma:SolidPeso molecular:696.25INCB3344 R-isomer
INCB3344 is a potent CCR2 antagonist. INCB3344 R-isomer is the R-isomer of INCB3344.Fórmula:C29H34F3N3O6Pureza:98%Cor e Forma:SolidPeso molecular:577.59CKLF1-C27 TFA
CKLF1-C27 peptide activates ERK1/2 via CCR4, competes with CKLF1, promotes HUVEC growth, and has psoriasis research potential.Fórmula:C153H244F3N39O39Cor e Forma:SolidPeso molecular:3310.8CH-0076989
CAS:CH-0076989 is a chemokine receptor CCR3 agonist.Fórmula:C24H22Br2N2O2Cor e Forma:SolidPeso molecular:530.25
